Failed Back Surgery Syndrome Medications on a Pharmacy Lien: Attorney Guide

James Wong — Founder & Pharmacist, LienScripts | March 26, 2026 | 8 min read

Failed back surgery syndrome (FBSS) produces ongoing medication needs that prove the original injury caused permanent damage despite surgical intervention. The long-term medication record is critical evidence for continued injury and high lien value in PI cases.

Failed Back Surgery Syndrome Medications on a Pharmacy Lien

Failed back surgery syndrome (FBSS) — persistent or recurrent pain after spinal surgery — produces an ongoing, multi-drug medication requirement that proves the original traumatic injury caused damage that surgical intervention could not fully resolve. For personal injury attorneys, the FBSS medication record is among the most powerful evidence of permanent injury because it documents continuous pharmacological treatment extending months to years beyond the surgery that was supposed to provide relief.

• FBSS affects 10-40% of patients who undergo spinal surgery, with persistent pain requiring ongoing medication management (Thomson, 2013, Pain Practice; PMID: 22776283)
• The ongoing medication requirement after failed surgery proves the original traumatic injury caused structural damage that remains unresolved — not that the surgeon made an error
• FBSS medication protocols typically include neuropathic pain agents, opioid therapy, muscle relaxants, anti-inflammatory agents, and psychological medications — 4 to 7 concurrent drugs
• Treatment duration is measured in years, with many FBSS patients requiring indefinite medication management
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that documents the pre-surgical medication profile, post-surgical profile, and ongoing FBSS medication needs as a continuous narrative for demand packages

Why FBSS Medication Records Prove Permanent Injury

The central legal argument in FBSS cases is straightforward: the patient underwent major spinal surgery — the most aggressive treatment available — and still requires daily medication for the same condition. The ongoing medication need after surgery is evidence that the original injury caused permanent structural damage. According to James Wong, PharmD, founder of LienScripts, "When a patient is on five medications two years after a spinal fusion, the pharmacy record tells a story no defense expert can dismiss — surgery was tried, surgery was not enough, and the patient still requires daily pharmaceutical intervention to manage the consequences of the original injury."

[!KEY] The FBSS medication record proves permanent injury through a simple, undeniable logic: the patient underwent the most aggressive available treatment (spinal surgery), and still requires ongoing multi-drug medication management. The continued prescriptions are evidence that the original traumatic injury caused damage beyond what surgery could repair.

Neuropathic Pain Medications: Documenting Persistent Nerve Damage

Persistent neuropathic pain is the hallmark of FBSS. The neuropathic medication profile after surgery documents that nerve damage from the original injury was not resolved by surgical decompression.

Gabapentinoids:

• Gabapentin (Neurontin) — continued at high doses (1800-3600 mg daily) after surgery. When gabapentin was prescribed before surgery and continues at the same or higher dose afterward, this documents surgical failure to resolve the neuropathic component.
• Pregabalin (Lyrica) — FDA-approved for neuropathic pain (FDA label, NDA 021446). A 2017 study in the European Spine Journal found that neuropathic pain persists in a significant proportion of post-surgical spine patients and responds to gabapentinoid therapy (PMID: 28012043).

Antidepressants at analgesic doses:

• Duloxetine (Cymbalta) — an SNRI increasingly used as a first-line agent for post-surgical neuropathic pain. FDA-approved for chronic musculoskeletal pain and multiple neuropathic pain conditions.
• Amitriptyline or nortriptyline — tricyclic antidepressants at analgesic doses (25-75 mg nightly) for persistent radicular pain and sleep disruption.

Topical agents:

• Lidocaine patches — applied to the surgical site and areas of persistent radiculopathy
• Compounded topical creams — multi-agent formulations (gabapentin/ketamine/lidocaine) for localized FBSS pain
• Capsaicin patches — high-concentration capsaicin for desensitization of peripheral nerve terminals

[!TIP] Compare the pre-surgical and post-surgical neuropathic medication profiles in the pharmacy record. If gabapentin was at 1200 mg before surgery and is now at 3600 mg after surgery, the dose escalation documents that surgery not only failed to resolve nerve pain but that the pain may have worsened — critical evidence for FBSS case valuation.

Opioid Therapy: Long-Term Pain Management Documentation

Many FBSS patients require chronic opioid therapy — a treatment decision that reflects the severity of their ongoing pain and the failure of non-opioid alternatives.

• Long-acting opioids — extended-release morphine, oxycodone ER, or buprenorphine patches for baseline pain control
• Short-acting opioids — oxycodone or hydrocodone/acetaminophen for breakthrough pain episodes
• Opioid rotation — switches between opioid agents (documented in the pharmacy record) indicate tolerance development and the need for ongoing optimization

Documentation value: Chronic opioid therapy for FBSS — managed by a pain management specialist with regular monitoring — documents that the patient's pain is severe enough to warrant the risks associated with long-term opioid use. A 2019 study in Pain found that FBSS patients on chronic opioid therapy had significantly higher pain scores and lower functional status than post-surgical patients who recovered successfully (PMID: 30431554).

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Chronic opioid therapy in an FBSS patient is not a prescribing preference — it is a documented clinical determination that the patient's pain is severe, refractory to multiple non-opioid approaches, and requires the most aggressive pharmacological management available. Every monthly opioid fill is evidence of continued, unresolved injury."

[!KEY] Chronic opioid therapy after failed back surgery — documented through monthly fills in the pharmacy lien record — proves that the patient's pain is severe enough to warrant the risks of long-term opioid use. This is a physician's ongoing clinical determination of severe, refractory pain that defense counsel cannot dismiss.

Muscle Relaxants and Anti-Spasticity Agents

Post-surgical muscle spasm and chronic paraspinal muscle dysfunction are common in FBSS:

• Baclofen — for chronic spasticity affecting the paraspinal musculature and lower extremities
• Tizanidine — for spinal-level muscle spasm, often dosed at night for sleep benefit
• Cyclobenzaprine — continued for chronic muscle guarding around the surgical site

Anti-Inflammatory Medications

Chronic inflammation around surgical hardware, at the fusion site, and in adjacent spinal segments produces ongoing anti-inflammatory medication needs:

• Celecoxib (Celebrex) — scheduled daily NSAID for chronic post-surgical inflammation. The daily dosing pattern (as opposed to as-needed use) documents chronic inflammatory pathology.
• Topical diclofenac — for localized application at the surgical site
• Oral corticosteroid bursts — for acute flares, documented by periodic steroid fill patterns in the pharmacy record

Psychological Medications: Documenting the Impact of Chronic Pain

FBSS is strongly associated with depression, anxiety, and sleep disruption. Medications initiated after the failed surgery document the psychological impact of persistent, unresolved pain:

• Sertraline or escitalopram — SSRIs for chronic pain-related depression
• Trazodone — for chronic pain-related sleep disruption
• Hydroxyzine — for anxiety and as a sleep adjunct

Adjacent Segment Disease Medications

A well-recognized complication of spinal fusion is adjacent segment disease (ASD) — accelerated degeneration of the spinal segments above and below the fusion. ASD medications document that the original injury and subsequent surgery have created a cascading spinal condition:

• New or escalated neuropathic agents for pain at levels different from the original surgery
• Additional muscle relaxants for spasm at adjacent segments
• Potential second surgical medication cycle if revision surgery is required

The Pharmacy Lien as Permanent Injury Evidence

A pharmacy lien through LienScripts captures the full FBSS medication timeline — from pre-surgical prescriptions through the ongoing post-surgical regimen. The multi-year record provides:

• Pre-surgical baseline — documents what the patient was taking before surgery attempted to resolve the condition
• Post-surgical escalation — documents medication additions and dose increases after surgical failure
• Chronicity evidence — continuous fills over months and years prove the condition is permanent
• Life care plan foundation — the established medication regimen provides the basis for projecting lifetime medication costs

The MERIT (Medication Evaluation & Rationale for Injury Treatment) report for FBSS cases presents the pre-surgical, post-surgical, and ongoing medication profiles as a continuous narrative, highlighting the contrast between the expected surgical outcome and the actual pharmacological reality.

Frequently Asked Questions